clinical trial · NCT07229612
A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase2·not yet recruiting·n = 200
Malignant Solid TumorsSHR-4298 Injection
brief summary
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-4298 injection in patients with malignant solid tumors.
started
Nov 1, 2025
primary completion
Nov 1, 2028
completion
Nov 1, 2028
last updated
Nov 17, 2025
official title
A Multicenter, Open-label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4298 Injection in Patients With Malignant Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol